Company intelligence / Profile preview
Metacen Therapeutics
- Ownership
- Private
- Development stage
- Phase 2
Overview
Metacen Therapeutics has developed over fifty nutraceutical products with proven clinical efficacy, including compounds that capture methylglyoxal for the treatment of a range of metabolic and age-related diseases. Clinical trials have demonstrated efficacy in reducing advanced glycation end-products and improving outcomes in metabolic conditions.[1][2]
- Therapeutic areas
- Metabolic DisordersOtherPsychiatryGastroenterologyCardiovascularNeurology
- Modalities
- Nutraceuticals[2][3]Small molecules (MGO-capturing compounds)[6]Probiotics[2]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Metacen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metacen Therapeutics.